Cerebral perfusion markers in full-term neonates as a measure of Hypoxic-Ischemic Encephalopathy during and immediately following Hypothermia Treatment

Abstract

Hypoxic-Ischaemic Encephalopathy (HIE) is a leading cause of neonatal mortality and morbidity. Therapeutic Hypothermia (TH) is the only treatment for HIE, which has reduced the rate of mortality and morbidity although still around fifty per cent of infants affected die or have a neurodevelopmental disability, such as cerebral palsy. Every infant with HIE receives the same TH protocol: 72 hours at 33.5 degrees Celsius, before being rewarmed slowly over 12 hours. The infants with moderate-severe HIE are at the highest risk of disability or death. Should it be possible to identify those infants at greatest risk during the TH, they could be targeted for modified TH treatment or for additional a..